Condition: Urinary Tract Infections · Bacteremia · Antibiotic Resistant Infection · Sponsor: Lund University
To evaluate if the combination of pivmecillinam and clavulanic acid (PAC) is non-inferior to ciprofloxacin, trimethoprim-sulfamethoxazole or ertapenem as step down oral therapy in patients with febrile UTI caused by extended spectrum beta-lactamase (ESBL) producing Enterobacterales (EPE).
This description comes directly from the study's public registry record.
Oskar Ljungquist, M.D, PhD · +46424063182 · oskar.ljungquist@med.lu.se
Jonas Tverring, M.D, PhD · +46424062673 · jonas.tverring@med.lu.se
Always discuss trial participation with your own doctor first.
| Helsingborg hospital | Helsingborg, Sweden | Recruiting |
| Kristianstad hospital | Kristianstad, Sweden | Recruiting |
| Skåne University Hospital, Lund | Lund, Sweden | Recruiting |
| Skåne University Hospital, Malmö | Malmö, Sweden | Recruiting |
| Västmanland hospital Västerås | Västerås, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05224401